Caris & Co Initiates Coverage on St. Jude (STJ)
More News related to STJ
- Notable Analyst Rating Changes 11/19: PSUN, LPX, SJM, SAFM Upgraded; SUN, SOL, GLW, CTRP Downgraded
- Jefferies Starts St. Jude Medical (STJ) at Hold
- St. Jude Medical Announces Japanese Approval and Launch of Victory Family of Pacemakers
- Short Seller Chanos Eyes Medical Sector
- Datascope Reports Sharply Higher Non-GAAP Sales and Earnings From Continuing Operations in the First Quarter of Fiscal 2009
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Caris & Co initiates coverage on St. Jude (NYSE: STJ) with a Buy. Price target $55.
St. Jude Medical, Inc. (St. Jude) develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain.
Related Categories
New CoverageStocks Mentioned
+2.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
